A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with S. aureus bacteremia
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs AB SA01 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2018 According to an AmpliPhi Biosciences Corporation media release, the company intends to initiate this trial in 2019.
- 27 Sep 2018 New trial record
- 17 Sep 2018 According to an AmpliPhi Biosciences Corporation media release, FDA is in general agreement with the design of proposed this clinical trial and no additional preclinical or clinical data are required to proceed with both trials.